MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Autophagic modulation by rosuvastatin prevent rotenone induced neurotoxicity as an in vitro model of Parkinson’s disease

W. Jang (Gangneung, Korea)

Meeting: 2016 International Congress

Abstract Number: 1842

Keywords: Alpha-synuclein, Cell death

Session Information

Date: Thursday, June 23, 2016

Session Title: Neuropharmacology

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: We investigated effects of statin on autophagy markers and evaluated the neuroprotective effect of rosuvastatin from rotenone induced neurotoxicity.

Background: Recently, autophagy pathway is regarded as important mechanism in pathogenesis of Parkinson’s disease (PD) and modulation of autophagy may be a novel strategy for the treatment of PD. Statin has been reported to have neuroprotective effect through anti-oxidant, anti-apoptotic, and anti-inflammatory mechanism and statin could also modulate autophagy signaling in various models.

Methods: As an in vitro model of PD, We adapted the rotenone-induced neurotoxicity model in SH-SY5Y cells. We measured cell viability using an MTT assay, Annexin V/propidium iodide assay, and intracellular reactive oxygen species levels. To detect the expression of LC3 and α-synuclein, immnunoflorescence analysis was performed. Intracellular signaling proteins associated with autophagy were explored by immunoblot analysis.

Results: Rosuvastatin mono-treatment increased levels of mTOR independent/upstream autophagy markers, including beclin-1, AMPK, and ULK-1. Rotenone treatment of SH-SY5Y cells reduced their viability, increased reactive oxygen species levels, induced apoptosis and α-synuclein expression; simultaneous exposure to rosuvastatin significantly restored these effects. Rotenone enhanced mTOR expression and suppressed beclin-1 expression, indicating suppression of autophagic system. However, combined treatment with rosuvastatin also restored the beclin-1 expression and decreased mTOR expression.

Conclusions: We demonstrated the neuroprotective effect of statin in SH-SY5Y cells against rotenone-induced neurotoxicity and modulation of α-synuclein expression. The mechanism of neuroprotection is likely to be associated with enhanced autophagy. The neuroprotective effect of statin on rotenone-induced dopaminergic neurotoxicity with autophagy modulation provides a new therapeutic strategy for the treatment of PD.

To cite this abstract in AMA style:

W. Jang. Autophagic modulation by rosuvastatin prevent rotenone induced neurotoxicity as an in vitro model of Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/autophagic-modulation-by-rosuvastatin-prevent-rotenone-induced-neurotoxicity-as-an-in-vitro-model-of-parkinsons-disease/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/autophagic-modulation-by-rosuvastatin-prevent-rotenone-induced-neurotoxicity-as-an-in-vitro-model-of-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley